Heat Biologics Inc (HTBX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Heat Biologics Inc (HTBX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH135574D
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Heat Biologics Inc (Heat Biologics) is an immuno-oncology company that develops novel therapies to activate patient's immune system against cancer. The company develops immune pan-antigen cytotoxic therapy, which is a therapeutic vaccine used in the treatment of cancer and infectious diseases. Its pipeline products include HS-110, which is used to treat non-small cell lung cancer, and HS-410 that is used in the treatment of non-muscle invasive bladder cancer. Heat Biologics conducts multiple clinical trials in various indications. The company's product serves various therapeutic areas such as non-small cell lung cancer, HIV infection, parasitic infections, and others. It partners with other pharma companies for its research and development activities. Heat Biologics is headquartered in Durham, North Carolina, the US.

Heat Biologics Inc (HTBX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deal Details

Venture Financing

Heat Biologics Raises USD0.5 Million in Venture Funding

Heat Biologics Raises USD5 Million In Venture Financing

Partnerships

Selexis and Pelican Therapeutics Enter into Agreement

Heat Biologics Enters into Agreement with Adaptive Biotechnologies

Licensing Agreements

University of Miami Enters into Licensing Agreement with Heat Biologics

Shattuck Labs Enters into Licensing Agreement with Heat Biologics

Heat Biologics Enters into Licensing Agreement with Columbia University

Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line

Heat Biologics Enters into Licensing Agreement with University of Miami

Equity Offering

Heat Biologics to Raise up to USD3.7 Million in Public Offering of Shares

Heat Biologics Prices USD2.5 Million of Public Offering of Shares

Heat Biologics Raises USD4 Million in Public Offering of Common Stock

Heat Biologics Raises USD7 Million in Public Offering of Shares

Heat Biologics Raises USD12.3 Million in Public Offering of Shares

Heat Biologics Completes Underwriters' Partial Exercise Of Over-Allotment Option For IPO Of Shares For USD27 Million

Acquisition

Heat Biologics Acquires 80% Stake in Pelican Therapeutics

Heat Biologics Inc-Key Competitors

Heat Biologics Inc-Key Employees

Heat Biologics Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Financial Announcements

Feb 28, 2018: Heat Biologics Reports Fiscal Year 2017 Financial Results

Nov 13, 2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update

May 11, 2017: Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017

Mar 31, 2017: Heat Biologics Reports Fiscal Year 2016 Financial Results

Corporate Communications

Oct 23, 2017: Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards

Jul 03, 2017: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics

Jan 04, 2017: Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer

Product News

06/28/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award

03/16/2017: Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine

Clinical Trials

Nov 11, 2017: Heat Biologics Presents Follow-up Data on its ComPACT(TM) T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018

List of Tables

Heat Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Heat Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018

Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Heat Biologics Raises USD0.5 Million in Venture Funding

Heat Biologics Raises USD5 Million In Venture Financing

Selexis and Pelican Therapeutics Enter into Agreement

Heat Biologics Enters into Agreement with Adaptive Biotechnologies

University of Miami Enters into Licensing Agreement with Heat Biologics

Shattuck Labs Enters into Licensing Agreement with Heat Biologics

Heat Biologics Enters into Licensing Agreement with Columbia University

Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line

Heat Biologics Enters into Licensing Agreement with University of Miami

Heat Biologics to Raise up to USD3.7 Million in Public Offering of Shares

Heat Biologics Prices USD2.5 Million of Public Offering of Shares

Heat Biologics Raises USD4 Million in Public Offering of Common Stock

Heat Biologics Raises USD7 Million in Public Offering of Shares

Heat Biologics Raises USD12.3 Million in Public Offering of Shares

Heat Biologics Completes Underwriters' Partial Exercise Of Over-Allotment Option For IPO Of Shares For USD27 Million

Heat Biologics Acquires 80% Stake in Pelican Therapeutics

Heat Biologics Inc, Key Competitors

Heat Biologics Inc, Key Employees

Heat Biologics Inc, Subsidiaries

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com